Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 0
---
Filed pursuant to Rule 424(b)(5)

Registration No. 333-275991

PROSPECTUS SUPPLEMENT

(To prospectus dated December 26, 2023)

<div align='center'>10,925,000 Common Shares

CLEARMIND MEDICINE INC.</div>

We are offering pursuant to this prospectus
supplement and the accompanying prospectus 10,925,000 common shares, no par value, or the common shares, at an offering price of $0.20
per Common Share.

Our Common Shares are currently traded on the
Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On November 18, 2025, the last reported sale price of our Common
Shares on the Nasdaq was $0.216 per share.

Our Common Shares also trade on the Frankfurt
Stock Exchange, or FSE, under the symbol “CWY”. On November 18, 2025, the last reported sales price of our Common Shares on
the FSE was EUR 0.29 (approximately $0.34) per share.

The highest aggregate market value of the outstanding
Common Shares held by non-affiliates within the 60 days prior to this prospectus supplement based on the closing price of the Common Shares
on the Nasdaq on September 19, 2025, as calculated in accordance with General Instruction I.B.5. of Form F-3, was approximately $26.2
million. During the twelve calendar months immediately prior to and including the date of this prospectus supplement, we sold securities
with an aggregate market value of $2,165,916 pursuant to General Instruction I.B.5. of Form F-3.

We are an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, and have elected to comply with certain reduced public company reporting requirements.

Investing in the securities involves a high degree of risk. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of information that should be considered in connection with an investment in the Common Shares.

Neither the Securities and Exchange Commission nor any state or other securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

|                                  |     | Per    
 Common 
 Share  |